Pacific Point Advisors LLC Sells 1,454 Shares of Cencora, Inc. $COR

Pacific Point Advisors LLC cut its position in shares of Cencora, Inc. (NYSE:COR) by 24.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,469 shares of the company’s stock after selling 1,454 shares during the quarter. Pacific Point Advisors LLC’s holdings in Cencora were worth $1,397,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Cencora by 13.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after acquiring an additional 5,543 shares during the period. Acadian Asset Management LLC increased its stake in Cencora by 947.5% in the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after purchasing an additional 232,539 shares during the period. Mediolanum International Funds Ltd lifted its position in Cencora by 133.0% in the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after purchasing an additional 32,138 shares during the last quarter. Segment Wealth Management LLC purchased a new stake in shares of Cencora during the third quarter valued at approximately $4,830,000. Finally, Synergy Asset Management LLC purchased a new stake in shares of Cencora during the third quarter valued at approximately $10,093,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 20,316 shares of company stock worth $7,151,265 in the last three months. 0.38% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday. Wells Fargo & Company increased their target price on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a report on Tuesday. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Finally, Bank of America lowered their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research report on Monday, January 5th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $399.00.

Cencora Price Performance

COR stock opened at $360.59 on Friday. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. Cencora, Inc. has a 1 year low of $237.71 and a 1 year high of $377.54. The firm has a 50-day moving average of $347.51 and a 200 day moving average of $328.35. The company has a market cap of $69.95 billion, a P/E ratio of 43.34, a PEG ratio of 1.62 and a beta of 0.68.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same quarter in the prior year, the business earned $3.73 EPS. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is currently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.